Table of Contents Table of Contents 2 Introduction 4 Radiodermatitis - Overview 5 Radiodermatitis - Therapeutics Development 6 Radiodermatitis - Therapeutics Assessment 12 Radiodermatitis - Companies Involved in Therapeutics Development 19 Radiodermatitis - Drug Profiles 22 Radiodermatitis - Dormant Projects 32 Radiodermatitis - Discontinued Products 33 Appendix 34

List of Tables Number of Products under Development for Radiodermatitis, H2 2018 7 Number of Products under Development by Companies, H2 2018 9 Number of Products under Development by Universities/Institutes, H2 2018 10 Products under Development by Companies, H2 2018 11 Products under Development by Universities/Institutes, H2 2018 12 Number of Products by Stage and Target, H2 2018 14 Number of Products by Stage and Mechanism of Action, H2 2018 16 Number of Products by Stage and Route of Administration, H2 2018 18 Number of Products by Stage and Molecule Type, H2 2018 19 Radiodermatitis - Pipeline by Daiichi Sankyo Co Ltd, H2 2018 20 Radiodermatitis - Pipeline by Foresee Pharmaceuticals Co Ltd, H2 2018 20 Radiodermatitis - Pipeline by Matrix Biomed Inc, H2 2018 21 Radiodermatitis - Pipeline by SK Chemicals Co Ltd, H2 2018 21 Radiodermatitis - Pipeline by Sunny Pharmtech Inc, H2 2018 22 Radiodermatitis - Dormant Projects, H2 2018 33 Radiodermatitis - Discontinued Products, H2 2018 34List of Figures Number of Products under Development for Radiodermatitis, H2 2018 7 Number of Products under Development by Companies, H2 2018 8 Number of Products by Targets, H2 2018 13 Number of Products by Stage and Targets, H2 2018 13 Number of Products by Mechanism of Actions, H2 2018 15 Number of Products by Stage and Mechanism of Actions, H2 2018 15 Number of Products by Routes of Administration, H2 2018 17 Number of Products by Stage and Routes of Administration, H2 2018 17 Number of Products by Stage and Molecule Types, H2 2018 19

Daiichi Sankyo Co Ltd Foresee Pharmaceuticals Co Ltd Matrix Biomed Inc SK Chemicals Co Ltd Sunny Pharmtech Inc